Chief Technical Officer and co-founder of Nemdx

Protein-Nucleic Acid Interactions: A Paradigm Shift

Host: E. Buratti

In this presentation, we embark on a journey through the intricate world of Protein-Nucleic Acid Interactions, exploring a transformative shift in the life sciences industry. We begin with an introduction to the speaker, followed by an overview of the topics we will explore: the study of cellular components and the modern biotechnology paradigm known as the“Omics Framework.”

Delving deeper into cellular components, we emphasize the importance of understanding their details, encompassing size, 3D structure, and functional activity. Central to our discussion is the pivotal role of detecting components of interest, with a spotlight on binding specificity and the often overlooked energy dynamics in binding interactions.

Market needs are addressed, revealing unmet demands for precise diagnostic procedures in various fields, from pandemics to neurology, and raising questions about the status of personalized medicine. We underscore the necessity for a clearer understanding of protein interactions in pathological conditions.
Next, we explore the current binding approaches, including antibodies, aptamers, mass spectrometry, next- generation sequencing, and imaging techniques like PET and FISH. We critically assess their effectiveness in meeting market demands.

Shifting paradigms is at the heart of our presentation as we introduce our innovative approach to address market needs. We showcase proprietary data from our tools which offer the highest specificity to selected targets. Leveraging our proprietary digital algorithmic platform, we emphasize the deterministic nature of our approach, setting us apart from conventional methods relying on random antibody and aptamer generation processes. Nemdx’ synthetic analytes, exhibiting unparalleled precision and strong affinities with targeted protein amino- acid sequences, represent a game-changing approach. We provide evidence of our recent achievements, particularly in the realm of neurodegenerative diseases, such as ALS.

In conclusion, this presentation should serve as stimulus to challenge the status-quo, addressing market needs and fostering collaborative efforts to advance the field.


Hundreds of videos, tens of playlists providing free scientific content worldwide